---
figid: PMC9576967__CCR3-10-e6392-g002
pmcid: PMC9576967
image_filename: CCR3-10-e6392-g002.jpg
figure_link: /pmc/articles/PMC9576967/figure/ccr36392-fig-0001/
number: FIGURE 1
figure_title: ''
caption: COVID‐19 activates the cytokine release pathway through the ACEII receptor,
  Ibratinib, Nivolumab, and Ruxolitinib inhibit cytokine through the inhibit of BTK,
  PD‐L1 and JAK2 receptor, respectively. ACEII, angiotensin‐converting enzyme II;
  BTK, Bruton's tyrosine kinase; JAK2, Janus Kinase II; PD‐L1, Programmed death‐ligand
  1.
article_title: 'Cancer patients and targeted therapy during COVID‐19 pandemic: A descriptive
  case series study.'
citation: Kasra Khodadadi, et al. Clin Case Rep. 2022 Oct;10(10):e6392.
year: '2022'

doi: 10.1002/ccr3.6392
journal_title: Clinical Case Reports
journal_nlm_ta: Clin Case Rep
publisher_name: John Wiley and Sons Inc.

keywords:
- case series
- COVID‐19
- immunotherapy
- malignant disease
- targeted therapy

---
